SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating geopolitical tensions in the Middle East, particularly around Iran's oil infrastructure and the critical Strait of Hormuz, are causing significant supply disruption fears. The community is actively discussing potential price spikes and market volatility, with some anticipating a prolonged oil rally while others foresee a sharp correction.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is trending on intense speculation surrounding the imminent Phase 3 REGAL trial results for its potential "curative" AML treatment, GPS, amplified by recent strong commentary from its CEO on the drug's adaptive immunotherapy platform. Investors are keenly watching for a potential Big Pharma acquisition and a major short squeeze, as discussions at a key industry summit further fuel optimism.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is gaining traction as fears of AI-driven disruption to online travel agencies diminish, with reports suggesting OpenAI is shifting away from direct booking towards third-party app integration, prompting multiple analyst upgrades that highlight the company's robust platform and upcoming stock split.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares ($SOXL) is experiencing extreme volatility amid heightened geopolitical tensions impacting oil prices and broader market sentiment. The community is divided between those anticipating further declines and others viewing the significant dip as a prime opportunity to accumulate, believing in the robust, underlying demand for semiconductors driven by AI despite current market jitters.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are actively accumulating SCO, a 2x inverse crude oil ETF, anticipating that the recent geopolitical premium driving elevated oil prices is unsustainable. The community is betting on an eventual significant pullback in crude, expecting that headline-driven spikes will fade as broader economic concerns and potential de-escalation in the Middle East weigh on demand and supply dynamics.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing intense community debate following its founder's critical comments on the CLARITY Act and the announcement of a LayerZero partnership, alongside new retail adoption in Switzerland, polarizing investors between strong long-term conviction and concerns over its recent market performance.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending due to consistent inflows into its spot ETFs and favorable regulatory developments, such as Japan classifying it as a financial asset, signaling increased institutional interest. The community remains divided, with many actively accumulating during price dips in anticipation of a rally, while others voice strong skepticism regarding its underlying value and potential for dilution.

TripAdvisor, Inc. is an online travel company, which owns and operates a portfolio of online travel brands. It operates through the following segments: Brand Tripadvisor, Viator, and TheFork. The Brand Tripadvisor segment offers travelers and experience seekers an online global platform for travelers to discover, generate, and share authentic user-generated content. The Viator segment enables travelers to discover and book iconic, unique, and memorable experiences from experience operators around the globe. The TheFork segment provides an online marketplace that enables diners to discover and book online reservations. The company was founded by Nicholas Shanny and Stephen Kaufer in February 2000 and is headquartered in Needham, MA.

TripAdvisor Inc.

Activist investor Starboard Value, holding over 9% of shares, is demanding a board overhaul and exploring a full company sale or divestiture of key segments like Viator, citing management's underperformance and slow AI adoption. This aggressive stance is fueling community speculation and volatility, especially after a recent dip following the rejection of prior buyout proposals.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI is trending amidst strong community discussion, fueled by its recent spot trading launch on major exchanges and the anticipation of multiple SUI ETFs requiring significant reserves. Investors are actively accumulating, positioning SUI as a potential 'next Solana' due to its robust Layer 1 technology, even as some debate its past performance.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as escalating geopolitical tensions and recent weak economic data fuel widespread bearish sentiment for the Nasdaq 100, prompting community discussion around using the inverse ETF to hedge against a potential market downturn and a perceived 'AI bubble' top.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.</li><li>BofA contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."&nbsp;</li><li>Under the settlement, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li></ul>Shares of vaccine maker Moderna (MRNA) rallied 16% on Wednesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma over a vaccine patent row which has left analysts divided.Under the <a href="https://stocktwits.com/news-articles/markets/equity/mrna-shares-rally-after-hours-on-settlement-deal-over-vaccine-patent-row/cZderPnRIPy">settlement</a>, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation, the company said on Tuesday. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion.<h2 class="st-heading-2">Analyst Take</h2>Citi analyst Geoff Meacham views Moderna's settlement with Arbutus as not the best-case scenario of an outright win but better than feared. The news is likely to come as a relief to many investors, the analyst told investors in a research note, while adding that it thinks the settlement removes an overhang for the stock. Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.BofA, likewise, contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."The structure leaves "a contingent tail" as Moderna could owe an additional payment of up to $1.3 billion if further litigation affirms liability, noted the analyst, who reiterated an ‘Underperform’ rating and $31 price target on Moderna shares.<h2 class="st-heading-2">Settlement Deal</h2>The settlement announced on Tuesday resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/farm-stock-sinks-to-48-year-lows-what-triggered-the-collapse/cZd9tBARId3">FARM Stock Sinks To 48-Year Lows – What Triggered The Collapse?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock

The news is likely to come as a relief to many investors, Citi told investors in a research note. 

Equity

The news is likely to come as a relief to many investors, Citi told investors in a research note. 


Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading Volume - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume - Still a Buy...

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

(RTTNews) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant...

<ul class="summary-bullets"><li>Moderna said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.&nbsp;</li><li>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li><li>The remaining $1.3 billion payout is subject to further litigation.</li></ul>Shares of vaccine maker Moderna (MRNA) rallied after hours on Tuesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma.The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5178901572623640&amp;symbol=MRNA">said</a> that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.<a href="https://stocktwits.com/symbol/ABUS">Shares of Arbutus</a> fell 8% after hours at the time of writing while shares of Genevant’s parent <a href="https://stocktwits.com/symbol/ROIV">Roivant Sciences</a> gained nearly 1%. Meanwhile, shares of MRNA rallied 11%.<h2 class="st-heading-2">Settlement Agreement</h2>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion."Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," said Moderna CEO Stéphane Bancel.The company now expects to end the year with $4.5 to $5.0 billion in cash and cash equivalents. The total projected liquidity available to the company at the end of 2026 will be $5.4 to $5.9 billion, it added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 65% over the past 12 months. Meanwhile, ABUS and ROIV added 37% and 174%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/autozone-shares-dive-post-earnings-but-wells-fargo-sees-buying-opportunity/cZdeYkuRIPt">AutoZone Shares Dive Post-Earnings But Wells Fargo Sees A Buying Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.

Western Standard LLC Makes New $2.31 Million Investment in Arbutus Biopharma Corporation $ABUS

Western Standard LLC bought a new position in Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

Arbutus Biopharma (NASDAQ:ABUS) Shares Pass Above 200-Day Moving Average - Should You Sell...

Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology.On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna's...

Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma Corporation (NASDAQ:ABUS - Get Free Report) saw some unusual options trading activity on Tuesday. Stock investors purchased 5,605 call options on the stock. This is an increase of...

<ul class="summary-bullets"><li>The verbal ruling was delivered on January 15, without written reasons, the company said.</li><li>The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued.</li><li>The company does not expect the ruling to impact outcomes of its patent infringement cases against Moderna.</li></ul>Arbutus Biopharma Corp. (ABUS) stock crashed more than 18% on Friday after the European Patent Office (EPO) revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.This marked the <a href="https://stocktwits.com/symbol/ABUS">ABUS stock’s</a> biggest intraday decline since July 2020.The verbal ruling was delivered on January 15 without written reasons, Arbutus said. The EPO ruling reverses two earlier decisions that had upheld an amended version of the patent EP 2279254. According to Google Patents, it covers “Novel lipid formulations for nucleic acid delivery.”The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued. Arbutus acknowledged that the decision could affect certain European legal actions against Moderna, including a case in Switzerland and a proceeding before the Unified Patent Court in which the patent is being asserted.<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> (MRNA) jumped 7%, while <a href="https://stocktwits.com/symbol/MRK">Merck</a> (MRK) traded 2% lower.<h2 class="st-heading-2">Impact Outside Europe</h2>Arbutus stressed that the revocation was based on the EPO’s “added matter” standard, which does not apply in other jurisdictions.As a result, the company does not expect the ruling to impact the timing or potential outcomes of its patent infringement cases against Moderna in the United States, Japan, or Canada, a separate Unified Patent Court case not involving the patent, or its ongoing litigation against Pfizer and BioNTech in the U.S.<h2 class="st-heading-2">Retail Reaction</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/ABUS_jpg_f665738876.webp" alt="ABUS.jpg">One user sees the drop as an opportunity to take up fresh positions.<stembedurl>https://stocktwits.com/LS172/message/642060814</stembedurl>One user said it’s all noise and nothing has changed ‘other than the bad headline’.<stembedurl>https://stocktwits.com/EdDwg/message/642040053</stembedurl>The stock has gained around 20% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-jfbr-stock-surge-today/cmUlvsnR4B0">Why This Penny Stock Is On Track To Gain For First Time In 10 Sessions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Plug Power said it was impacted by the speed and development of hydrogen economy.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.04	--	--	N/A
Q3 '25	-$0.03	-$0.04	-33.33%	MISSED
Q2 '25	-$0.05	$0.01	121.05%	BEAT
Q1 '25	-$0.10	-$0.13	-25.00%	MISSED
Q4 '24	-$0.08	-$0.07	9.68%	BEAT

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ABUS News

ABUSArbutus Biopharma Corp